A vaccine composed of a 100 aa MUC1 peptide administered with SB-AS2 adjuvant (a mixture of MPL and QS-21 in an oil-in-water emulsion) to 16 patients with resected or locally advanced pancreatic cancer induced weak MUC1-specific humoral and T-cell responses in some patients [140]. The gene discussed is MUC1; the disease is pancreatic neoplasm.